Physician profile
John Bloch
NPI 1386148559
$2,176.37
in general payments reported to CMS, 2019-2025
15 companies · $605 in 2025
The $605 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $613 · 2023: $479 · 2024: $254 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.58 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $461.95 | 2021-2025 | Entyvio, Gattex |
| Medtronic, INC. | $340.82 | 2022-2023 | Endoflip |
| Abbvie INC. | $243.60 | 2021-2025 | Skyrizi |
| Celgene Corporation | $185.08 | 2022-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $161.53 | 2025 | Terlivaz |
| Gilead Sciences, INC. | $155.55 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.58 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $141.66 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $125.89 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $81.98 | 2021-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $38.47 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $27.92 | 2024 | Voquezna |
| Pfizer INC. | $25.31 | 2024 | |
| Blueprint Medicines Corporation | $23.51 | 2023 | Ayvakit |
| Ardelyx, INC. | $15.52 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.